periprocedural plasma fibrinogen levels and coronary stent outcome
Clicks: 253
ID: 168924
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
253 views
44 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #89 of 437 articles by views in renewable energy
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 437 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Aim: Percutaneous intervention is one of the treatment option for coronary artery disease. Reinfarction and restenosis is one of the complication of the procedure. So this study was conducted to assess plasma fibrinogen levels pre- and post coronary stenting and its relation with outcome.
Methods: After obtaining informed consent, venous blood samples were collected at three timed points in relation to stenting – 24 h before, 24 h after and 72 h after stenting to assess fibrinogen levels. Patients were followed up for six months. Repeat revascularization, myocardial infarction and symptomatic angina were considered as major adverse clinical events.
Results: 57 patients who underwent successful stenting and followed up for six months up were included in the study. Mean age was 53 years and 87.7% were males and 29.8% were diabetics. Baseline plasma fibrinogen level was significantly high in patients who developed repeat angina and myocardial infarction after the stenting [288.64 ± 59.43 vs 393.75 ± 32.97 mg/dL, p = 0.003] and it remained high during serial assessment [322.74 ± 63.92 vs 422.00 ± 55.28 mg/dL, 326.23 ± 65.81 vs 419.50 ± 45.82 mg/dL, 0.008, 0.012 respectively]. Patients who developed adverse events denied any drug default.
Conclusion: We conclude that plasma fibrinogen plays a significant role in the development of adverse events following stenting shown by high level of plasma fibrinogen in patients who developed adverse events.
| Reference Key |
kavitha2015indianperiprocedural
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;S. Kavitha;M.G. Sridhar;S. Satheesh |
| Journal | renewable energy |
| Year | 2015 |
| DOI |
10.1016/j.ihj.2015.06.006
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.